INAB
HEALTHCAREIN8bio Inc
$1.58-0.04 (-2.47%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INAB Today?
No stock-specific AI insight has been generated for INAB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.17$5.61
$1.58
Fundamentals
Market Cap$16M
P/E Ratio—
EPS$-4.44
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume75K
Avg Volume (10D)—
Shares Outstanding9.8M
INAB News
20 articles- Cash runway, pipeline and going concern at IN8bio (NASDAQ: INAB)Stock Titan·May 8, 2026
- IN8bio Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 7, 2026
- IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical ConferencesYahoo Finance·May 6, 2026
- RedChip's Biotech Virtual Investor Conference Replays Now AvailableYahoo Finance·Apr 21, 2026
- RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsYahoo Finance·Apr 7, 2026
- IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026Yahoo Finance·Mar 12, 2026
- IN8bio to Present at TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating OfficerYahoo Finance·Feb 9, 2026
- IN8bio to Present at Upcoming Investor and Scientific Conferences in FebruaryYahoo Finance·Feb 3, 2026
- IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed GlioblastomaYahoo Finance·Jan 12, 2026
- IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell EngagerYahoo Finance·Dec 19, 2025
- IN8bio Reports Third Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Nov 6, 2025
- IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New SiteYahoo Finance·Oct 29, 2025
- IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune IndicationsYahoo Finance·Oct 27, 2025
- IN8bio Reports Second Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Aug 7, 2025
- IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma TrialYahoo Finance·Jun 9, 2025
- IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free SurvivalYahoo Finance·Jun 2, 2025
- IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025Yahoo Finance·May 14, 2025
- IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical ProductsYahoo Finance·May 12, 2025
All 20 articles loaded
Price Data
Open$1.68
Previous Close$1.62
Day High$1.69
Day Low$1.50
52 Week High$5.61
52 Week Low$1.17
52-Week Range
$1.17$5.61
$1.58
Fundamentals
Market Cap$16M
P/E Ratio—
EPS$-4.44
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume75K
Avg Volume (10D)—
Shares Outstanding9.8M
About IN8bio Inc
IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—